Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | S. Murphy | M. Mercuri | M. O’Donoghue | C. Ruff | L. Grip | M. Shi | H. Rutman | G. Kania | O. Čermák
[1] T. Brennan,et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. , 2014, The American journal of medicine.
[2] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[3] D. Xavier,et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .
[4] G. Breithardt,et al. Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy , 2013, Annals of Internal Medicine.
[5] L. Køber,et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study , 2013, BMJ Open.
[6] Gerhard Hindricks,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[7] Jeroen J. Bax,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.
[8] S. Yusuf,et al. Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation , 2010, Circulation.
[9] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[10] S. Yusuf,et al. Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range , 2008, Circulation.
[11] E. Hylek,et al. Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation: Potential Insights Into Risk From a Comparative Analysis of SPORTIF III Versus SPORTIF V , 2008, Stroke.
[12] G. Lip,et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.
[13] Gregory W Albers,et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. , 2007, Archives of internal medicine.
[14] M. Pfeffer,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.
[15] A. Waldo. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2008 .